Med. praxi. 2018;15(2):66-70 | DOI: 10.36290/med.2018.014
Management of benign prostatic hyperplasia in primary care
- Urologická klinika 2. LF UK a FN Motol, Praha
Benign prostatic hyperplasia represents the most common urological condition among middle-aged and elderly men. Although diagnosisand treatment of benign prostatic hyperplasia belongs to urologist, essential knowledge of pathogenesis, symptomatology and treatmentoptions may facilitate care of these patients. This article summarises contemporary treatment options with focus on farmacotherapy.
Keywords: benign prostatic hyperplasia, LUTS, alpha-blockers, 5-alpha-reductase inhibitors, phosphodiesterase 5 inhibitors,
phytotherapy
Published: May 1, 2018 Show citation
References
- Vuichoud C, Louchlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015; 22(Suppl. 1): 1-6.
- McNeal JE. The zonal anatomy of the prostate. Prostate. 1981; 2(1): 35-49.
Go to original source... 
Go to PubMed... - Gravas S, Bach T, Drake M, et al. EAU Guidelines on Treatment of Non-neurogenic male LUTS, 2017. Dostupné z: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
- Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006; 147(Suppl. 2): S88-119. Go to original source...
- Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008; 62(10): 1547-1559. Go to original source... Go to PubMed...
- Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014; 11(6): 1554-1566. Go to original source... Go to PubMed...
- Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13. Go to original source...
- Roehrborn CG, Ray P. Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men. Prostate Cancer Prostatic Dis. 2006; 9(4): 432-438. Go to original source...
- McConell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998; 338(9): 557-563. Go to original source...
- Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010; 57(1): 123-131. Go to original source... Go to PubMed...
- Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008; 180(3): 1030-1032; discussion 1032-1033. Go to original source... Go to PubMed...
- Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012; 61(5): 917-925. Go to original source... Go to PubMed...
- Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58(3): 384-397. Go to original source... Go to PubMed...